New CEO at ThromboGenics
This article was originally published in Scrip
Executive Summary
ThromboGenics (Belgium), a biotechnology company focused on novel therapies for eye disease, vascular disease and cancer, has announced that Dr Patrik De Haes, currently chief operating officer, has been appointed to succeed Professor Désiré Collen as the company's new chief executive officer, effective September 1st. Professor Collen founded ThromboGenics as a spin-out of the University of Leuven and has led the company since its inception.